{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:58:58Z","timestamp":1790207938020,"version":"4.1.0"},"reference-count":46,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"11","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2020,10,22]]},"DOI":"10.1167\/tvst.9.11.27","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T16:30:44Z","timestamp":1603384244000},"page":"27","source":"Crossref","is-referenced-by-count":37,"title":["Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders"],"prefix":"10.1167","volume":"9","author":[{"given":"Chen-rei","family":"Wan","sequence":"first","affiliation":[{"name":"Clearside Biomedical, Alpharetta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Kapik","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Alpharetta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Houston, Retina Consultants of America; Blanton Eye Institute, Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Henry","sequence":"additional","affiliation":[{"name":"Retina Consultants of Houston, Retina Consultants of America; Blanton Eye Institute, Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Barakat","sequence":"additional","affiliation":[{"name":"Retinal Consultants of Arizona, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Shah","sequence":"additional","affiliation":[{"name":"Midwest Eye Institute, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael V.","family":"Andino","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Alpharetta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Clearside Biomedical, Alpharetta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"12","key":"bib1","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Heal"},{"issue":"8","key":"bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of disease of retinal vein occlusion: Review of the literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye"},{"issue":"5","key":"bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3928\/23258160-20160324-01","article-title":"DRCR Protocol-T: Reconciling 1- and 2-year data for managing diabetic macular edema","volume":"47","author":"Wykoff","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"7","key":"bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"bib6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion 52-week results of the VIBRANT Study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"bib7","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"issue":"10","key":"bib8","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"issue":"10","key":"bib9","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"20","key":"bib12","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study","volume":"116","author":"Brown","year":"2006","journal-title":"Ophthalmology"},{"issue":"14","key":"bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"bib16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"issue":"1","key":"bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49?485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retin"},{"issue":"5","key":"bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","volume":"97","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol"},{"issue":"15","key":"bib20","first-page":"5063","article-title":"Suprachoroidal microinjection delivers triamcinolone acetonide to therapeutically-relevant posterior ocular structures and limits exposure in the anterior segment.","volume":"54","author":"Edelhauser","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"4","key":"bib21","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1167\/iovs.13-11747","article-title":"Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles","volume":"54","author":"Gilger","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol Retin"},{"key":"bib23","article-title":"Aflibercept with or without suprachoroidal CLS-TA for diabetic macular edema: a randomized, double-masked, parallel-design, controlled study","author":"Barakat","journal-title":"Ophthalmol Retin"},{"issue":"8","key":"bib24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"Suprachoroidal triamcinolone acetonide for diabetic macular edema: the HULK Trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retin"},{"issue":"7","key":"bib25","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3, randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"issue":"10","key":"bib26","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: The multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"bib27","first-page":"835","article-title":"Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex) in non-infectious posterior uveitis","volume":"8","author":"Yap","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"10","key":"bib28","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","article-title":"Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study","volume":"122","author":"Kempen","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"bib29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3341\/kjo.2012.26.5.362","article-title":"A three-year follow-up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema","volume":"26","author":"Cho","year":"2012","journal-title":"Korean J Ophthalmol"},{"issue":"12","key":"bib30","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/IAE.0000000000000726","article-title":"Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations","volume":"35","author":"Yang","year":"2015","journal-title":"Retina"},{"issue":"11","key":"bib31","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ophtha.2014.05.021","article-title":"Periocular corticosteroid injections in uveitis: effects and complications","volume":"121","author":"Sen","year":"2014","journal-title":"Ophthalmology"},{"issue":"10","key":"bib32","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.ophtha.2015.06.041","article-title":"The risk of intraocular pressure elevation in pediatric noninfectious uveitis","volume":"122","author":"Kothari","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2006.0067","article-title":"The etiology of steroid cataract","volume":"23","author":"James","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0886-3350(88)80150-0","article-title":"Calculating axial length in the aphakic and the pseudophakic eye","volume":"14","author":"Olsen","year":"1988","journal-title":"J Cataract Refract Surg"},{"issue":"6","key":"bib38","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1167\/iovs.15-16597","article-title":"Real-time monitoring of suprachoroidal space (SCS) following SCS injection using ultra-high resolution optical coherence tomography in guinea pig eyes","volume":"56","author":"Gu","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and closure kinetics of the suprachoroidal space following microneedle injection of liquid formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"bib40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3928\/23258160-20180831-07","article-title":"Suprachoroidal space alterations following delivery of triamcinolone acetonide: Post-hoc analysis of the phase 1\/2 HULK study of patients with diabetic macular edema","volume":"49","author":"Lampen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"1","key":"bib41","doi-asserted-by":"crossref","first-page":"e29692","DOI":"10.1371\/journal.pone.0029692","article-title":"Scleral thickness in human eyes","volume":"7","author":"Vurgese","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"bib42","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/IAE.0000000000001489","article-title":"Overview of the complications of high myopia","volume":"37","author":"Ikuno","year":"2017","journal-title":"Retina"},{"issue":"3","key":"bib43","doi-asserted-by":"crossref","first-page":"e93551","DOI":"10.1371\/journal.pone.0093551","article-title":"Scleral cross section area and volume and axial length","volume":"9","author":"Jonas","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"bib44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1167\/iovs.16-20742","article-title":"Is choroidal or scleral thickness related to myopic macular degeneration?","volume":"58","author":"Wong","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"8","key":"bib45","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/IAE.0000000000000947","article-title":"Scleral and choroidal thickness in secondary high axial myopia","volume":"36","author":"Shen","year":"2016","journal-title":"Retina"},{"issue":"2","key":"bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.exer.2009.11.001","article-title":"Dimensions of the human sclera: Thickness measurement and regional changes with axial length","volume":"90","author":"Norman","year":"2010","journal-title":"Exp Eye Res"},{"key":"bib10","first-page":"2376","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID Studies","volume-title":"Ophthalmology","author":"Heier","year":"2016;"},{"key":"bib34","article-title":"Regenxbio. Regenxbio reports first quarter 2020 financial results and operational highlights"},{"key":"bib35","volume-title":"Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020"},{"key":"bib36","article-title":"Clearside Biomedical. CLS-AX: Axitinib for Suprachoroidal Injection"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T16:31:03Z","timestamp":1603384263000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.9.11.27","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,22]]}}}